

# BMJ Open Towards tailoring of self-management for patients with chronic heart failure or chronic obstructive pulmonary disease: a protocol for an individual patient data meta-analysis

Nini H Jonkman,<sup>1</sup> Heleen Westland,<sup>1</sup> Jaap C A Trappenburg,<sup>1</sup> Rolf H H Groenwold,<sup>2</sup> Tanja W Effing-Tijdhof,<sup>3</sup> Thierry Troosters,<sup>4</sup> Job van der Palen,<sup>5</sup> Jean Bourbeau,<sup>6</sup> Tiny Jaarsma,<sup>7</sup> Arno W Hoes,<sup>2</sup> Marieke J Schuurmans<sup>1</sup>

**To cite:** Jonkman NH, Westland H, Trappenburg JCA, *et al*. Towards tailoring of self-management for patients with chronic heart failure or chronic obstructive pulmonary disease: a protocol for an individual patient data meta-analysis. *BMJ Open* 2014;**4**:e005220. doi:10.1136/bmjopen-2014-005220

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2014-005220>).

Received 7 March 2014  
Revised 21 April 2014  
Accepted 2 May 2014



CrossMark

For numbered affiliations see end of article.

#### Correspondence to

Nini H Jonkman;  
n.jonkman@umcutrecht.nl

## ABSTRACT

**Introduction:** Self-management interventions in patients with chronic conditions have received increasing attention over the past few years, yet the meta-analyses encountered considerable heterogeneity in results. This suggests that the effectiveness of self-management interventions must be assessed in the context of which components are responsible for eliciting the effect and in which subgroups of patients the intervention works best. The aim of the present study is to identify condition-transcending determinants of success of self-management interventions in two parallel individual patient data meta-analyses of self-management trials in patients with congestive heart failure (CHF) and in patients with chronic obstructive pulmonary disease (COPD).

**Methods and analysis:** Investigators of 53 randomised trials (32 in CHF and 21 in COPD) will be requested to share their de-identified individual patient data. Data will be analysed using random effects models, taking clustering within studies into account. Effect modification by age, sex, disease severity, symptom status, comorbid conditions and level of education will be assessed. Sensitivity analyses will be conducted to assess the robustness of the findings.

**Ethics and dissemination:** The de-identified individual patient data are used only for the purpose for which they were originally collected and for which ethical approval has been obtained by the original investigators. Knowledge on the effective ingredients of self-management programmes and identification of subgroups of patients in which those interventions are most effective will guide the development of evidence-based personalised self-management interventions for patients with CHF and COPD as well as with other chronic diseases.

**Trial registration number:** PROSPERO: CRD42013004698.

## Strengths and limitations of this study

- This individual patient data (IPD) meta-analysis will evaluate the effects of self-management interventions across two chronic conditions: patients with chronic heart failure and patients with chronic obstructive pulmonary disease.
- Embedding of the study in an international network and careful consideration of methodological challenges of the IPD approach have resulted in a robust design of data collection and analysis.
- Retrieval bias might occur if not all the original investigators are willing or able to participate and not all individual patient data can be included.

## INTRODUCTION

With the rising number of people suffering from one or more chronic conditions,<sup>1 2</sup> interventions to support self-management have received increasing attention over the past few years. Such interventions aim to teach patients the skills to actively participate in the management of their chronic condition and generally comprise skills for symptom monitoring, management of medication use and changing health behaviours.<sup>3</sup>

The evidence presented so far in meta-analyses seems to favour self-management interventions for improving a range of outcomes in various patient groups.<sup>4–10</sup> Yet several authors encountered considerable heterogeneity in the outcomes analysed,<sup>4 9</sup> sometimes leading to contradictory findings.<sup>11 12</sup> A recently published large randomised controlled trial (RCT) among patients with chronic obstructive pulmonary disease (COPD) even reported unexplained higher mortality rates among the patients in

the intervention group, who received one group session and multiple individual sessions addressing problem-solving techniques and lifestyle changes, followed up by telephone contacts.<sup>13</sup>

One explanation for those ambiguous findings might be the high variation across studies evaluating self-management interventions. Self-management interventions can be regarded as complex interventions.<sup>14</sup> The intervention studies differ not only in procedural aspects such as content, duration and intensity,<sup>14</sup> but also in the patient populations included and outcomes measured.<sup>15</sup> The question whether self-management interventions are effective cannot be answered without considering which components are responsible for eliciting the effect and identifying in which subgroups of patients the intervention is most effective. Few attempts have been made to identify determinants of success across conditions,<sup>15</sup> which is rather surprising since a majority of the patients with a chronic condition suffer from comorbidity.<sup>16 17</sup> Individual trials in different chronic conditions have reported large proportions of non-complying and non-responding patients.<sup>3</sup> Based on these results, the question arises if barriers to adhere to interventions and adopt self-management behaviour are disease-specific or transcend specific conditions.

The combination of studies in a meta-analysis or meta-regression might provide insight into which programme-specific components are likely to be effective. Intervention studies, however, may differ not only with regard to the intervention evaluated, but also with regard to characteristics of the population included. Comparisons of patient characteristics across studies based on aggregate data in a 'classical' meta-analysis may be subjective to ecological bias.<sup>18</sup> A meta-analysis of individual patient data (IPD) overcomes this potential drawback and enables a straightforward analysis of both subgroups of patients in whom the intervention will be most effective and the effects of relevant components of the studied (complex) interventions.<sup>19</sup> Sufficient power for analysing subgroups is warranted due to the larger numbers of patients included in the analyses, which overcomes the problems with limited power of subgroup analyses experienced in individual trials.<sup>19 20</sup> An IPD meta-analysis therefore seems an attractive approach for unravelling the determinants of success of self-management interventions.

In order to discover the determinants of success of self-management interventions for chronic disease 'at large' (ie, condition-transcending), the present study will initiate two parallel IPD meta-analyses of self-management trials in two different chronic conditions: in patients with chronic heart failure (CHF) and in patients with COPD. The focus will be on patients with CHF or COPD because of the large number of patients confronted with either one or both of these conditions<sup>2 21</sup> and the large number of available self-management trials. Although the management of these conditions differs considerably, both patient groups are

confronted with daily adherence to a drug treatment and lifestyle advice and monitoring of signs and symptoms is important for the prevention or timely detection of exacerbations.<sup>21 22</sup> This makes self-management an inevitable part of care for those patient groups.<sup>21 23</sup> In both conditions, self-management interventions are extensively studied, but the outcomes of published studies are heterogeneous.<sup>6 11</sup>

## Objectives

The present paper provides a detailed description of the rationale and design for this IPD meta-analysis. The primary objective is to identify programme-specific and patient-specific determinants of the effect of self-management interventions on health-related quality of life (HRQoL), mortality, all-cause and disease-related hospital admissions and days in hospital in patients with CHF and patients with COPD.

In addition to two independent analyses for self-management trials in patients with CHF and patients with COPD, we will compare the results in both patient groups and investigate the similarities and differences in determinants. The secondary objective is to identify programme-specific and patient-specific determinants of successful self-management interventions in chronic disease 'at large', that is, condition-transcendent determinants.

## METHODS AND ANALYSIS

### Identification of studies

An extensive literature search has been conducted in the electronic databases of PubMed, EMBASE and Cochrane Central Register on Controlled Trials, PsycINFO and CINAHL from January 1985 to June 2013. Medical Subject Heading (MeSH) terms and key words used in the title and abstract were 'chronic heart failure', 'chronic obstructive pulmonary disease', 'self-management', 'self-care', 'patient-education', 'randomised controlled trial' and synonyms (see online supplementary appendix 1 for PubMed search strategy as an example of the complete search terms). Reference lists of relevant systematic reviews were hand-searched and experts in the domain were consulted to ensure a complete coverage of relevant studies.

### Included studies

Studies included in this IPD meta-analysis are RCTs with concealed allocation to treatment. Inclusion criteria for patients are an established primary diagnosis of CHF or COPD according to the prevailing international clinical guidelines.<sup>21 23</sup> This IPD meta-analysis aims to determine patient-specific effect modifiers; therefore, no exclusion criteria apply with regard to, for example, disease severity or comorbidities.

Since a gold standard of which essential elements constitute a self-management intervention is lacking,<sup>24</sup> an extensive literature search was performed before an

international group of seven experts reached consensus during a conference meeting on essential components for defining 'self-management intervention'. This resulted in inclusion criteria for interventions, with included interventions requiring a minimum of two of the following components: (1) active stimulation of symptom monitoring, (2) education in problem solving skills (ie, self-treatment such as managing acute exacerbations, resource utilisation and stress/symptom management) and enhancement of (3) medication adherence, (4) physical activity, (5) dietary intake or (6) smoking cessation. The intervention selection is schematically presented in figure 1.

Studies are included in the IPD meta-analysis if they (1) studied an intervention which fulfilled the requirements of the definition of self-management intervention, (2) compared the self-management intervention to usual care or another self-management intervention, (3) reported data on one or more of the relevant outcomes for this IPD meta-analysis (see below), (4) followed patients for at least 6 months and (5) were reported in English, Dutch, French, German, Italian, Portuguese or Spanish.

### Methodological quality

Quality appraisal is performed by two independent researchers not involved in any of the primary studies. The methodological quality of the studies is assessed through three relevant criteria based on the 'Risk of bias' tool from the Cochrane Collaboration<sup>25</sup>:

1. Random concealed allocation to treatment;
2. Intention-to-treat analysis;
3. Other deviances (eg, discrepancies in baseline characteristics, high drop-out rates with unbalances between groups and risk of contamination).


Discrepancies between the two researchers are solved through discussion with a third researcher. Results of the quality appraisal will be applied in sensitivity analyses including only studies with a low risk of bias to assess the impact of studies of lower methodological quality.

### Data collection

Fifty-three RCTs (32 in CHF patients, 21 in patients with COPD) have been selected for this IPD meta-analysis (see online supplementary appendix 2 for a list of included studies). The original investigators are requested to participate in this IPD meta-analysis through an invitation by email, written in English, Spanish, Portuguese or Dutch. Email addresses have been obtained through contact details of recent publications or retrieval of affiliations. A reminder is sent after several weeks if no response is received, after which other investigators of the original trial will be approached. Investigators will be asked to send their encrypted data, preferably electronically, only after written agreement, by creating encrypted files (in a WinZip file). Standardised data collection forms with the minimum required data items are provided to investigators, but they can send their data in any format most convenient for them (eg, SAS, SPSS and Microsoft Excel spreadsheet). Additionally, investigators are asked to check the extracted intervention characteristics from their studies to ensure a correct interpretation of interventions.

The data items to be collected are based on clinical relevance, previously reported meta-analyses (programme-specific determinants) and subgroup analyses in RCTs (patient-specific determinants). Table 1 presents the data items investigators are requested to share.

**Figure 1** Inclusion criteria for interventions.



**Table 1** Data items investigators are requested to share

Study level <i>Methodology</i>	Study level <i>Intervention</i>	Patient level <i>Characteristics at baseline</i>	Patient level <i>Intervention as implemented</i>	Patient level <i>Outcomes</i>
<ul style="list-style-type: none"> <li>▶ Year of recruitment</li> <li>▶ Location of recruitment</li> <li>▶ Method of randomisation</li> <li>▶ Blinding to group assignment</li> </ul>	<ul style="list-style-type: none"> <li>▶ Mode(s) of delivery</li> <li>▶ Content covered in intervention</li> <li>▶ Number of planned contacts during intervention</li> <li>▶ Duration of the intervention</li> <li>▶ Type of training given to interventionists</li> </ul>	<ul style="list-style-type: none"> <li>▶ Sex</li> <li>▶ Age</li> <li>▶ Years since diagnosis</li> <li>▶ Disease severity (CHF=LVEF; COPD=FEV1%, FEV1, FVC)</li> <li>▶ Symptom status (CHF=NYHA class; COPD=dyspnoea)</li> <li>▶ Comorbid conditions</li> <li>▶ Level of education</li> <li>▶ Ethnic minority</li> <li>▶ Living alone</li> <li>▶ Self-efficacy</li> <li>▶ Depression</li> <li>▶ Body mass index</li> <li>▶ Smoking status</li> </ul>	<ul style="list-style-type: none"> <li>▶ Number of actual contacts with patient during intervention</li> <li>▶ Content covered with individual patient</li> <li>▶ Targeted behaviour achieved</li> <li>▶ Loss-to-follow-up and reason</li> </ul>	<ul style="list-style-type: none"> <li>▶ Health-related quality of life (score on instrument)</li> <li>▶ Mortality (yes/no; time-to-event)</li> <li>▶ All-cause hospital admissions (number; time-to-first-event)</li> <li>▶ Disease-related hospital admissions (number; time-to-first-event)</li> <li>▶ All-cause days in hospital (total number of days)</li> <li>▶ Disease-related days in hospital (total number of days)</li> </ul>

CHF, chronic/congestive heart failure; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FEV1%, predicted forced expiratory volume in 1 s; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Data will be saved in the original format as sent by the investigator and subsequently will be converted to a common SPSS format (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, V.20.0 Armonk, New York: IBM Corp) for data checking and recoding. Data of each trial will be checked with regard to the range of variables measured, extreme values, internal consistency, missing values and consistency with published reports. The details of the interventions as presented in [table 2](#) are cross-checked with trial protocols and published reports. Discrepancies with published results, missing data or inconsistencies will be verified with the original investigators and any problems resolved by consensus.

Across studies, variables might be coded differently and recoding may be necessary to create uniform categories in the combined dataset. To ensure the correct interpretation of original categories and a correct recoding, new categories are only coded after consultation of the original investigators. All datasets from individual trials will be assigned a unique trial ID before being merged into the central database.

### Project management

One of the major challenges in IPD meta-analyses is good communication across cultural and language barriers and careful management of and negotiation with collaborating investigators.<sup>20</sup> For this IPD meta-analysis, an international collaborative study group is established, the Tailoring of Self-management and E-health Individual Patient Data (TASTE-IPD) study group. From each original trial, one representative becomes a

member of the collaboration. Representatives of the trials will be invited to teleconferences (at least twice a year) and meetings scheduled during international

**Table 2** Determinants to be analysed

Determinants	
Programme-specific	<ul style="list-style-type: none"> <li>▶ Number of planned contacts</li> <li>▶ Duration of the intervention</li> <li>▶ Training given to interventionists (standardised/heterogeneous)*</li> <li>▶ Group contact with peers (y/n)*†</li> <li>▶ Keeping diaries for symptom-monitoring (y/n)‡</li> <li>▶ Goal-setting skills (y/n)*†</li> <li>▶ Problem-solving skills (y/n)*†</li> <li>▶ Support allocation skills (y/n)*</li> </ul>
Patient-specific	<ul style="list-style-type: none"> <li>▶ Sex</li> <li>▶ Age</li> <li>▶ Disease severity</li> <li>▶ Symptom severity</li> <li>▶ Number of comorbid conditions</li> <li>▶ Depression</li> <li>▶ Level of education</li> </ul> <p><i>Optional variables (only analysed if sufficient data available):</i></p> <ul style="list-style-type: none"> <li>▶ Recently diagnosed</li> <li>▶ Self-efficacy</li> <li>▶ Living status</li> <li>▶ Body mass index</li> <li>▶ Smoking status</li> </ul>

\*Based on self-management literature.

†Based on social cognitive theory.

‡Based on behavioural techniques.



conferences (annually). Separate teleconferences/meetings will be held for the COPD and CHF trials. During those meetings, major methodological decisions and (preliminary) results will be discussed. Between meetings, members of the study group are updated on study progress through newsletters. Before submission of a manuscript for publication, a draft version will be circulated among investigators to allow for comments, revision and approval. Publications are authored with the names of the investigators where possible and on behalf of the collaboration as a whole with names of other participating investigators listed in the acknowledgements. During the project, the collaboration might decide on new research questions which can be answered through a re-analysis of the combined database.

The project management team will be responsible for management decisions within the collaboration and will organise communication with investigators through mailings, teleconferences and meetings. Its members carry the responsibility for the decisions with regard to daily management of the study, collection of the individual data, development of the core dataset and statistical analysis. The project management team is supported by expert members, who are self-management experts in the fields of either CHF or COPD.

### Outcome measures

The present study will focus on various outcome measures. These include:

1. Change in HRQoL at 6 and at 12 months. A distinction is made between disease-specific and generic HRQoL to address the different assessment of HRQoL applied in the original studies;
2. Mortality (time-to-event, % death at 6 and at 12 months);
3. Hospitalised for any cause (time-to-event, % hospitalised at 6 and at 12 months);
4. Total number of days spent in hospital for any cause at 6 and at 12 months;
5. Hospitalised for resp. CHF or COPD (time-to-event, % hospitalised at 6 and at 12 months);
6. Total number of days spent in hospital for resp. CHF or COPD at 6 and at 12 months.

### Statistical analyses

First, statistical analyses will be performed for CHF and COPD studies separately to meet the primary objective, but the analyses will be similar. To address the secondary objective, analyses will be repeated combining the data from both patient groups to assess whether effect determinants transcend the specific chronic condition. An additional covariate will be included in the models below to indicate the specific condition. All analyses will be performed in R for Windows V.2.15.3 (R Development Core Team, Released 2013, Vienna, Austria: R Foundation for Statistical Computing), according to the intention-to-treat principle. Missing data in studies will be addressed by using multiple imputations

by chained equations.<sup>26</sup> Missing values will only be imputed within studies.

The IPD will be analysed using a one-stage approach, that is, simultaneously analysing all observations while accounting for clustering of observations within studies.<sup>27</sup> For time-to-event data, the effects of self-management will be quantified by estimating HR and 95% CI. Cox proportional-hazard models will be used to analyse the data, including a cluster statement to allow inter study variability. For binary outcome data (mortality, all-cause and disease-related hospital admissions), risk ratios and 95% CI will be estimated using log-binomial mixed-effects models. Effects on continuous outcomes (HRQoL and days in hospital) will be quantified by mean differences and 95% CI and will be estimated using linear mixed effects models. In the log-binomial and linear mixed-effects models, random intercepts and random slopes will be included to take clustering within studies into account. Heterogeneity is assessed with the  $I^2$  statistic.<sup>28</sup>

### Programme-specific determinants

To identify programme-specific determinants of self-management interventions, the aforementioned models are complemented with covariates for programme characteristics. Table 2 presents an overview of the potential programme-specific determinants to be studied. The programme-specific determinants are based on social cognitive theory,<sup>29</sup> self-management literature<sup>24 30 31</sup> and successful behavioural techniques.<sup>32</sup> Additionally, the intensity and duration of interventions will be studied, since these have shown to be related to outcomes in behavioural interventions.<sup>33</sup> Programme-specific determinants are considered significant if the p value is <0.05.

### Patient-specific determinants

The aforementioned models will be extended to study effect modification by patient characteristics. Effect modification implies that the effect of the intervention on an outcome differs depending on the value of a third variable, the effect modifier. This can be studied by including the interaction terms in the models. An overview of potential effect modifiers is presented in table 2. This is a selection of clinically relevant variables, which can be expected to have been collected across the majority of trials in a comparable manner. Next to age, sex, disease severity and symptom status, the present study will focus on comorbid conditions (with specific attention to depression) and level of education, as those variables have been shown to be related to change in self-management behaviour in chronic patients.<sup>34 35</sup> Since the amount of effect modifiers included in the models is restricted by the total number of patients included for analysis, the optional patient-specific effect modifiers will only be included if sufficient patient data are available.

To assess whether the effect of self-management is modified by prespecified patient characteristics, each

model will include interaction terms of the patient characteristics in [table 2](#). Hence, the independent variables in each model are the random intercepts and slopes for the individual studies, the self-management intervention, the specific patient characteristic and interaction terms (self-management by patient characteristics), with the outcome as a dependent variable. Coefficients of interaction terms will be presented with 95% CI.

### Sensitivity analysis

Sensitivity analysis will be performed to assess the robustness of the findings. Inclusion of aggregate data of studies for which IPD are unavailable will be performed to test whether IPD are representative of all eligible studies. A complete-case analysis will be carried out to assess the effects of imputing missing data. In addition, inclusion of only studies with a low risk of bias will be performed to assess the impact of studies of lower methodological quality on the findings. Adaptations to the statistical analysis plan will be made only after the study group has been consulted and consensus has been reached.

### ETHICS AND DISSEMINATION

The de-identified IPD are used only for the purpose for which they were originally collected and for which ethical approval has been obtained from the individual studies. In the case of re-analysis of de-identified patient data, informed consent is not deemed necessary. Data will be included in the IPD meta-analysis only after written agreement of the original investigator and after de-identification. Data will remain the property of the original investigators at all times, and they have the right to withdraw their data from the study. The shared datasets will not be used for purposes other than declared in the protocol without the permission of the original investigators. Data are considered confidential and will be stored on a secured location on the digital network of the UMC Utrecht that can only be accessed by the members of the project management team.

This project is embedded in the research line TASTE, which aims to enhance the effectiveness of self-management for chronic conditions.<sup>36</sup> Consolidation of generating high-quality scientific output is strengthened by collaboration with international universities, educational institutes and patient/provider organisations. Results of this IPD meta-analysis will be disseminated in international peer-reviewed journals and at international conferences.

### DISCUSSION

To the best of our knowledge, the present study will be the first IPD meta-analysis on comprehensive self-management interventions to be conducted across two chronic conditions: CHF and COPD. We aim to identify in each patient group which programme-specific and

patient-specific determinants modify the effects of self-management interventions on HRQoL, mortality and healthcare use. Our secondary aim is to identify which determinants transcend both conditions and are associated with better outcomes of self-management interventions in chronic disease 'at large'. This is crucial information in view of the common approaches in self-management strategies across conditions and the rising number of patients with multiple chronic conditions.<sup>16 17</sup>

A re-analysis of self-management trials on the level of individual patients is essential to study programme and patient characteristics as possible determinants of success.<sup>18</sup> IPD meta-analyses are still quite rare in the field of complex interventions,<sup>37–39</sup> even though the literature on the methodology of IPD meta-analyses is increasing.<sup>27</sup> Substantial efforts have been made to carefully design the present IPD meta-analysis and anticipate the limitations of the IPD approach. Based on the lessons learnt from other IPD meta-analyses in this area, the important methodological considerations are met as shown in [table 3](#).<sup>37–39</sup> With our extensive search strategy, we have minimised the chance of missing relevant trials. Since self-management interventions are complex interventions, a clear definition of inclusion and exclusion criteria is essential for a transparent selection of studies included. We carefully discussed and documented the reasons underlying our choice of the required data items, statistical plan and preplanned sensitivity analyses to ensure that we collect the necessary information to assess the robustness of findings and minimise bias.

Despite our careful methodological considerations, some of our methodological choices can be discussed. First, the choice of inclusion date. The earliest study included in our selection dates back to 1995, resulting in a time span of nearly 20 years over which individual trials were conducted. To ensure completeness, we have chosen not to exclude the first self-management trials, although the 'usual care' provided to control groups in these studies will not be comparable to the usual care that is more recent. Second, for our primary analysis, we have chosen to impute missing data only within studies. With this approach, we will limit our analysis to the studies which have provided data on the selected effect modifiers, which might introduce bias if data are not missing completely at random. Another solution might be to impute missing data across studies. Yet, the multi-level methods required to achieve this are quite novel and multiple imputation is generally recommended for imputing sporadic missing values instead of systematically missing data.<sup>40</sup> As non-collected data will be systematically missing in that specific study, we have chosen the conventional approach of multiple imputation within studies only. Third, the quality of our findings is highly dependent on the quality of the original design, the quality and completeness of the data and the level of detail provided by the original researchers.<sup>25</sup> Retrieval bias may occur if not all the original investigators are willing or able to participate and we cannot obtain all

**Table 3** Comparison of meta-analyses of individual patient data on self-monitoring/self-management

Study	Farmer <i>et al</i> <sup>37</sup> Self-monitoring of blood glucose	Heneghan <i>et al</i> <sup>38</sup> Self-monitoring of oral anticoagulation	Pickup <i>et al</i> <sup>39</sup> Self-monitoring of blood glucose	TASTE-IPD Self-management
Number of studies approached and declined <sup>19 27</sup>	100% participation	52% participation	100% participation	Ongoing
Systematic search <sup>27</sup>	± Limited syntax	+	± Limited syntax	+
Efforts to include non-published data <sup>20</sup>	+	+	–	–
Intention-to-treat analysis <sup>27</sup>	+	+	?	+
Clustering within studies preserved in analysis <sup>19</sup>	+	+	±	+
	Random intercepts in 1-stage model	2-stage model	Preservation in 1-stage model unclear	Random intercepts in 1-stage model
Handling missing data within studies and impact on results <sup>27</sup>	+	?	+/?	+
		No information handling missing data	No information impact missing data	
Impact of missing trials on results <sup>19 27</sup>	NA	?	NA	+
				Sensitivity analysis of aggregate data
Impact of quality assessment on results <sup>19</sup>	+	–	–	+
	Sensitivity analysis	No analysis	No analysis	Sensitivity analysis

NA, not applicable; +, present in study; ±, partly present in study; –, not present in study; ?, no information in publication.

IPD. Therefore, sensitivity analyses are planned to assess the impact on our findings.

With this planned IPD meta-analysis, we aim to advance our understanding of effectiveness of self-management interventions. Knowledge on the effective ingredients of programmes contributes to the development of evidence-based personalised self-management interventions. By identifying subgroups of patients in which self-management interventions are most effective, we will be better able to tailor future interventions and personalise care for patients with chronic disease.

#### Author affiliations

<sup>1</sup>Department of Rehabilitation, Nursing Science and Sports, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>2</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>3</sup>Department of Respiratory Medicine, Repatriation General Hospital, Daw Park, South Australia, Australia

<sup>4</sup>Department of Rehabilitation Sciences, Catholic University of Leuven, Leuven, Belgium

<sup>5</sup>Department of Research Methodology, Measurement and Data Analysis, University of Twente, Enschede, The Netherlands

<sup>6</sup>Respiratory Epidemiology Unit, McGill University, Montreal, Quebec, Canada

<sup>7</sup>Department of Social and Welfare Studies, Linköping University, Linköping, Sweden

**Contributors** All authors participated in developing the study design. NHJ and HW selected the studies. NHJ wrote the first draft of this manuscript. HW, JCAT, RHHW, TWE-T, TT, JP, JB, TJ, AWH and MJS revised several versions of the manuscript. All authors approved the final version.

**Funding** This work was supported by the Dutch Ministry of Health, Welfare and Sports, ZonMw grant number 520001002.

**Competing interests** None.

**Ethics approval** This IPD meta-analysis has been exempted from the Medical Research Involving Human Subjects Act of the Netherlands by the Medical Ethics Research Committee of the University Medical Center Utrecht, the Netherlands.

**Provenance and peer review** Not commissioned; peer reviewed for ethical and funding approval prior to submission.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

#### REFERENCES

- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006;3:e442.
- Mathers C, Boerma T, Ma Fat D. *The global burden of disease: 2004 update*. Geneva, Switzerland: World Health Organization, 2008.
- Newman S, Steed L, Mulligan K. Self-management interventions for chronic illness. *Lancet* 2004;364:1523–37.
- Gibson PG, Powell H, Coughlan J, *et al*. Self-management education and regular practitioner review for adults with asthma. *Cochrane Database Syst Rev* 2003;1:CD001117.
- Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. *BMC Cardiovasc Disord* 2006;6:43.
- Effing T, Monnikhof EM, van der Valk PD, *et al*. Self-management education for patients with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2009;4:CD002990.
- Deakin T, McShane CE, Cade JE, *et al*. Group based training for self-management strategies in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2005;2:CD003417.
- Duke SA, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2009;1:CD005268.

9. Malanda UL, Welschen LM, Riphagen II, *et al.* Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. *Cochrane Database Syst Rev* 2012;1:CD005060.
10. Chodosh J, Morton SC, Mojica W, *et al.* Meta-analysis: chronic disease self-management programs for older adults. *Ann Intern Med* 2005;143:427–38.
11. Ditewig JB, Blok H, Havers J, *et al.* Effectiveness of self-management interventions on mortality, hospital readmissions, chronic heart failure hospitalization rate and quality of life in patients with chronic heart failure: a systematic review. *Patient Educ Couns* 2010;78:297–315.
12. Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes self-management training. *Diabetes Educ* 2008;34:815–23.
13. Fan VS, Gaziano JM, Lew R, *et al.* A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. *Ann Intern Med* 2012;156:673–83.
14. Anderson R. New MRC guidance on evaluating complex interventions. *BMJ* 2008;337:a1937.
15. Warsi A, Wang PS, LaValley MP, *et al.* Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. *Arch Intern Med* 2004;164:1641–9.
16. van Oostrom SH, Picavet HS, van Gelder BM, *et al.* Multimorbidity and comorbidity in the Dutch population—data from general practices. *BMC Public Health* 2012;12:715.
17. Marengoni A, Angleman S, Melis R, *et al.* Aging with multimorbidity: a systematic review of the literature. *Ageing Res Rev* 2011;10:430–9.
18. Simmonds MC, Higgins JP. Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. *Stat Med* 2007;26:2982–99.
19. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010;340:c221.
20. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. *Eval Health Prof* 2002;25:76–97.
21. McMurray JJ, Adamopoulos S, Anker SD, *et al.* ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2012;14:803–69.
22. Bourbeau J, van der Palen J. Promoting effective self-management programmes to improve COPD. *Eur Respir J* 2009;33:461–3.
23. Global Initiative for Chronic Obstructive Lung Disease (GOLD). *Global strategy for the diagnosis, management and prevention of COPD*. 2014. <http://www.goldcopd.org/> (accessed 7 Mar 2014).
24. Barlow J, Wright C, Sheasby J, *et al.* Self-management approaches for people with chronic conditions: a review. *Patient Educ Couns* 2002;48:177–87.
25. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0*. The Cochrane Collaboration, 2011.
26. van Buuren S, Groothuis-Oudshoorn K. Mice: Multivariate Imputation by Chained Equations in R. *J Stat Soft* 2011;45:3.
27. Simmonds MC, Higgins JP, Stewart LA, *et al.* Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. *Clin Trials* 2005;2:209–17.
28. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
29. Bandura A. Health promotion by social cognitive means. *Health Educ Behav* 2004;31:143–64.
30. Bodenheimer T, Lorig K, Holman H, *et al.* Patient self-management of chronic disease in primary care. *J Am Med Assoc* 2002;288:2469–75.
31. Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. *Ann Behav Med* 2003;26:1–7.
32. Michie S, Abraham C, Whittington C, *et al.* Effective techniques in healthy eating and physical activity interventions: a meta-regression. *Health Psychol* 2009;28:690–701.
33. Conn VS, Cooper PS, Ruppert TM, *et al.* Searching for the intervention in intervention research reports. *J Nurs Scholarsh* 2008;40:52–9.
34. Jerant A, Kravitz R, Moore-Hill M, *et al.* Depressive symptoms moderated the effect of chronic illness self-management training on self-efficacy. *Med Care* 2008;46:523–31.
35. Smeulders ES, van Haastregt JC, Ambergen T, *et al.* Heart failure patients with a lower educational level and better cognitive status benefit most from a self-management group programme. *Patient Educ Couns* 2010;81:214–21.
36. Trappenburg J, Jonkman N, Jaarsma T, *et al.* Self-management: One size does not fit all. *Patient Educ Couns* 2013;92:134–7.
37. Farmer AJ, Perera R, Ward A, *et al.* Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. *BMJ* 2012;344:e486.
38. Heneghan C, Ward A, Perera R, *et al.* Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. *Lancet* 2012;379:322–34.
39. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ* 2011;343:d3805.
40. Resche-Rigon M, White IR, Bartlett JW, *et al.* Multiple imputation for handling systematically missing confounders in meta-analysis of individual participant data. *Stat Med* 2013;32:4890–905.